Sign Up Today and Learn More About Aviceda Therapeutics Stock
Invest in or calculate the value of your shares in Aviceda Therapeutics or other pre-IPO companies through EquityZen's platform.
Aviceda Therapeutics Stock (AVTH)
Aviceda Therapeutics is a late-stage, pre-clinical biotech company developing drugs for treating glyco-immune diseases.
About Aviceda Therapeutics Stock
Founded
2018
Headquarters
Cambridge, MA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Aviceda Therapeutics Press Mentions
Stay in the know about the latest news on Aviceda Therapeutics
Aviceda Therapeutics Appoints Dr. Emmett T. Cunningham, Jr. To Board
citybiz • Apr 09, 2025
Aviceda Therapeutics Appoints Dr. Jeffrey Nau as CEO
citybiz • Apr 02, 2025
Sialic-acid ligand decorated therapeutics
patents • Apr 02, 2025
Aviceda Therapeutics Appoints Industry Veteran Dr. Jeffrey Nau as Chief Executive Officer to Lead Next Phase of Growth and Innovation
biospace • Apr 01, 2025
Polysialic acid-polymer conjugate and nanoparticle
patents • Feb 07, 2025
Aviceda Therapeutics Management
Leadership team at Aviceda Therapeutics
Co-Founder, CEO & President, Executive Board Director
Mohamed Genead
Co-Founder and CTO
Michael Tolentino
Join now and verify your accreditation status to gain access to:
- Aviceda Therapeutics Current Valuation
- Aviceda Therapeutics Stock Price
- Aviceda Therapeutics Management
- Available deals in Aviceda Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Aviceda Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Aviceda Therapeutics Revenue and Financials
- Aviceda Therapeutics Highlights
- Aviceda Therapeutics Business Model
- Aviceda Therapeutics Risk Factors
- Aviceda Therapeutics Research Report from SACRA Research
Trading Aviceda Therapeutics Stock
How to invest in Aviceda Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Aviceda Therapeutics through EquityZen funds. These investments are made available by existing Aviceda Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Aviceda Therapeutics stock?
Shareholders can sell their Aviceda Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
